Kymera Therapeutics, Inc.

Healthcare · Biotechnology · United States

Last price 126.63 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 10.81B

Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports

Kymera Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body’s own natural protein degradation system. It engages in developing KT-621, an oral STAT6 degrader in Phase 2b clinical trials for moderate to severe atopic dermatitis, asthma, COPD, EoE, CRSwNP, CSU, PN, BP, and others; KT-579, an oral IRF5 degrader in Phase 1 trials for autoimmune diseases such as systemic lupus erythematosus, rheumatoid...